Affiliation:
1. Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department
Abstract
Due to the widespread drug resistance of M. tuberculosis (MTB), it is necessary to assess the possibility of using drugs with antimycobacterial activity previously used in other pathologies, e.g. clofazimine, in anti-tuberculosis chemotherapy regimens.The aim was to determine the phenotypic sensitivity to clofazimine of clinical strains of MTB with different spectrum of drug resistance.Methods. Clofazimine sensitivity was studied for 75 MTB clinical strains by serial microdilutions in Middlebrook 7H9 liquid medium (50 were drug-susceptible, 25 have MDR and pre-XDR), with estimation of MIC50, MIC90 and epidemiologic cut-off value of MIC (ECOFF).Results. The growth of most MTB strains (76%) was suppressed by clofazimine concentrations ranging from 0.06 to 0.125 μg/ml. The growth of 50% (MIC50) and 90% (MIC90) of drug-sensitive strains was inhibited by clofazimine concentrations of 0.125 and 0.25 μg/ml, respectively, while the growth of drug-resistant strains was inhibited by 0.125 and 0.5 μg/ml, respectively. The ECOFF value was 0.25 μg/ml.Conclusion. Clofazimine even in low concentrations inhibits the growth of MTB clinical strains regardless of sensitivity to other antimycobacterial drugs. The obtained data serve as an additional basis for the use of clofazimine in the complex treatment of tuberculosis, including MDR and XDR pathogens.
Reference33 articles.
1. Bogorodskaya E.M., Kudlai D.A., Litvinov V.I. Problemy lekarstvennoi ustoichivosti mikobakterii / Pod red.: E.M. Bogorodskoi, D.A. Kudlaya, V.I. Litvinova. – M.: MNPTsBT, 2021. – 504 s.
2. Vasil'eva I.A., Belilovskii E.M., Borisov S.E., Sterlikov S.A. Tuberkulez s mnozhestvennoi lekarstvennoi ustoichivost'yu vozbuditelya v stranakh mira i v Rossiiskoi Federatsii // Tuberkulez i bolezni legkikh. – 2017. – № 11. – S. 5-18.
3. Galkin V.B., Sterlikov S.A., Balasanyants G.S., Yablonskii P.K. Dinamika rasprostranennosti tuberkuleza s mnozhestvennoi lekarstvennoi ustoichivost'yu // Tuberkulez i bolezni legkikh. – 2017. – № 3. – S. 5-12.
4. Barry V.C., Belton J.G., Conalty M.L. et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity // Nature. – 1957. – Vol. 179. – P. 1013-1015.
5. Bvumbi M.V. Activity of riminophenazines against Mycobacterium tuberculosis: A review of studies that might be contenders for use as antituberculosis agents // Chem. Med. Chem. – 2020. – Vol. 15, № 23. – P. 2207-2219. doi: 10.1002/cmdc.202000580.